Friday, September 29, 2023


Biotechnology News Magazine

Veracyte: Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis

Review article and commentary in AnnalsATS reinforce clinical utility of genomic test to improve confidence in IPF diagnosis, in conjunction with HRCT and clinical factors

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical practice guideline highlights the role of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis (IPF). The document, Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline, appears online in the American Journal of Respiratory and Critical Care Medicine(AJRCCM). Additionally, a new review article and separate commentary on the Envisia Genomic Classifier appear online in AnnalsATS. AJRCCM and AnnalsATS are official journals of the American Thoracic Society.

“We are encouraged by the extensive discussion of the Envisia Genomic Classifier in this updated guideline and the related articles regarding diagnosis of IPF and other interstitial lung diseases,” said Giulia C. Kennedy, Ph.D., Veracyte’s global chief scientific officer and chief medical officer. “We believe these discussions reinforce the intended clinical value of our test, which is to enable physicians to make a confident diagnosis of IPF, without the need for invasive surgery.”

The Envisia classifier detects a genomic pattern of usual interstitial pneumonia (UIP), a critical factor that can help physicians differentiate IPF from other interstitial lung diseases (ILDs), without the need for surgery. The test was developed using RNA whole-transcriptome sequencing and machine learning and is covered by Medicare.

“IPF and other ILDs are often extremely challenging to diagnose,” said Fayez Kheir, M.D., a pulmonologist at Massachusetts General Hospital and lead author of the review article. “The Envisia test, with its ability to help rule in UIP, may help give physicians more confidence in an IPF diagnosis, when used in conjunction with HRCT and clinical factors. Having a confident IPF diagnosis is important because it can help these patients to obtain the therapy they need in a timely manner.”

More than 40 percent of the guideline authors voted to specifically recommend genomic classifier testing for use in clinical practice. According to the guideline, “Those who favored genomic classifier testing believed that the high specificity provided important diagnostic information that can be used in MDD [multi-disciplinary discussion] and, therefore, may reduce the need for additional sampling for histopathology diagnosis.”

The guideline points to a meta-analysis of data for the Envisia test, which showed a specificity for identifying a UIP pattern of 92 percent and a sensitivity of 68 percent in patients with an ILD of unknown type following clinical evaluation and high-resolution computed tomography (HRCT).

Approximately 200,000 patients are evaluated for suspected ILDs each year in the United States and Europe. ILDs are serious, lung-scarring diseases that are often difficult to diagnose; IPF is among the most common and dangerous of these illnesses. In a U.S. survey of people with ILDs including IPF, 55 percent of patients reported at least one misdiagnosis prior to receiving an accurate diagnosis and more than a third (38 percent) reported at least two misdiagnoses. This diagnostic challenge often leads to treatment delays, misdiagnoses, patient distress, and added healthcare expense. Accurate and timely diagnosis of IPF is especially important given the availability of drugs to slow progression of the disease.

About Veracyte

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine